Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

The purpose of this pre-approval access program is to give talquetamab monotherapy (treatment with single drug) to participants with relapsed or refractory multiple myeloma (a type of cancer that begins in plasma cells [white blood cells that produce antibodies] which has returned or difficult to treat) who have relapsed on or are refractory to all locally available and clinically appropriate treatment and who are not eligible for a clinical trial.

Inclusion Criteria:Participant diagnosed with relapsed or refractory multiple, myelomaParticipant exhausted all commercially approved and clinically appropriate treatment options, and is ineligible for a clinical trial